Ser496
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser496  -  AMPKA1 (rat)

Site Information
AtPQRSGsISNYRSC   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450431

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 9 ) , mass spectrometry ( 1 , 2 , 3 , 9 ) , mutation of modification site ( 6 , 9 ) , phospho-antibody ( 4 , 5 , 6 , 7 , 8 , 9 ) , western blotting ( 4 , 5 , 6 , 7 , 8 )
Disease tissue studied:
pancreatic cancer ( 6 ) , pancreatic carcinoma ( 6 )
Relevant cell line - cell type - tissue:
adipose tissue ( 2 ) , Chang liver (cervical) ( 9 ) , COS (fibroblast) ( 6 ) , heart ( 2 , 8 ) , IEC-6 (epithelial) ( 1 ) , INS-1 (pancreatic) ( 6 ) , intestine ( 2 ) , kidney ( 2 ) , liver ( 2 , 3 , 5 ) , lung ( 2 ) , MEF (fibroblast) ( 6 ) , myocyte-heart ( 4 , 7 ) , pancreas ( 2 ) , spleen ( 2 ) , stomach ( 2 )

Upstream Regulation
Regulatory protein:
Akt1 (rat) ( 7 ) , LKB1 (human) ( 7 )
Putative in vivo kinases:
Akt1 (rat) ( 8 ) , PKACA (rat) ( 6 )
Kinases, in vitro:
Akt1 (human) ( 8 ) , AMPKA1 (rat) ( 6 , 8 ) , LKB1 (mouse) ( 9 ) , PKACA (human) ( 6 )
Treatments:
angiotensin_2 ( 4 ) , anoxia ( 9 ) , colforsin ( 6 ) , hypoxia ( 7 ) , IBMX ( 6 ) , insulin ( 8 ) , ischemia ( 8 ) , liothyronine ( 4 ) , osmotic_stress ( 9 ) , peptide inhibitor ( 6 ) , phenobarbital ( 5 ) , serum ( 1 ) , wortmannin ( 6 )

Downstream Regulation
Effects of modification on AMPKA1:
enzymatic activity, inhibited ( 5 , 6 , 8 )

References 

1

Courcelles M, et al. (2013) Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions. Mol Syst Biol 9, 669
23712012   Curated Info

2

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

3

Demirkan G, et al. (2011) Phosphoproteomic Profiling of In Vivo Signaling in Liver by the Mammalian Target of Rapamycin Complex 1 (mTORC1). PLoS One 6, e21729
21738781   Curated Info

4

Jiang SY, et al. (2010) A distinct AMP-activated protein kinase phosphorylation site characterizes cardiac hypertrophy induced by L-thyroxine and angiotensin II. Clin Exp Pharmacol Physiol 37, 919-25
20497424   Curated Info

5

Shindo S, Numazawa S, Yoshida T (2007) A physiological role of AMP-activated protein kinase in phenobarbital-mediated constitutive androstane receptor activation and CYP2B induction. Biochem J 401, 735-41
17032173   Curated Info

6

Hurley RL, et al. (2006) Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem 281, 36662-72
17023420   Curated Info

7

Soltys CL, Kovacic S, Dyck JR (2006) Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am J Physiol Heart Circ Physiol 290, H2472-9
16428351   Curated Info

8

Horman S, et al. (2006) Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem 281, 5335-40
16340011   Curated Info

9

Woods A, et al. (2003) Identification of phosphorylation sites in AMP-activated protein kinase (AMPK) for upstream AMPK kinases and study of their roles by site-directed mutagenesis. J Biol Chem 278, 28434-42
12764152   Curated Info